Image Place holder

Jing-Yi Chern, MD, ScM

Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center

Cancer Focus: Cervical Cancer, Endometrial (Uterine) Cancer , Ovarian Cancer , Vaginal Cancer , Vulvar Cancer

Dr. Chern is a Gynecologic Oncologist at Moffitt Cancer Center.  After earning her Master’s Degree in Biochemistry and Molecular Biology at the Johns Hopkins University Bloomberg School of Public Health in Baltimore, Dr. Chern completed her Medical Degree at the University of South Florida College of Medicine. She subsequently completed her Residency in Obstetrics and Gynecology at the University of South Florida, where she served as Administrative Chief Resident and Scientific Review Committee Member.  Dr. Chern completed her Gynecologic Oncology Fellowship at New York University School of Medicine, where she earned a Certificate in Translational Research Methodologies under the Clinical and Translational Science Institute.  Her clinical focus is to provide personalized and comprehensive care for women with gynecologic cancers, with a special interest in the surgical management of advanced malignancies.  Dr. Chern also emphasizes the utilization of minimally invasive surgery, including the robotic platform.  Dr. Chern’s research interest includes evaluating quality and safety measures to improve surgical outcomes in patients with malignancies.  Dr. Chern has worked as part of a multidisciplinary team to develop new protocols and safety measures with the goal of improving post-operative outcomes and patient satisfaction.  In addition, her research is involved in understanding genetic factors associated with gynecologic malignancies to improve and guide patient care.

Education & Training


  • New York University School of Medicine - Gynecologic Oncology
  • Memorial Sloan Kettering - Galloway Fellowship


  • University of South Florida - Obstetrics & Gynecology

Medical School:

  • University of South Florida(MD, - MD)
Participating Trials

A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Condition: Gynecological Tumor
Intervention: Anetumab Ravtansine (BAY 94-9343) (); Avastin (Bevacizumab); Bevacizumab (); Taxol (paclitaxel); paclitaxel ()

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecol Oncol. 2019 Nov.156(2):349-356. Pubmedid: 31771865.
  • Madden N, Frey MK, Joo L, Lee J, Musselman K, Chern JY, Blank SV, Pothuri B. Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients. Am J Obstet Gynecol. 2019 Mar.220(3):253.e1-253.e7. Pubmedid: 30557552.
  • Chern JY, Lee SS, Frey MK, Lee J, Blank SV. The influence of BRCA variants of unknown significance on cancer risk management decision-making. J Gynecol Oncol. 2019 Jul.30(4):e60. Pubmedid: 31074248. Pmcid: PMC6543104.
  • Chern JY, Boyd LR, Blank SV. Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors. Oncology (Williston Park). 2017 Mar;31(3):229-236. Pubmedid: 28299760.
  • Frey MK, Ellis AE, Koontz LM, Shyne S, Klingenberg B, Fields JC, Chern JY, Blank SV. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum. Gynecol Oncol. 2017 Aug;146(2):386-391. Pubmedid: 28602549.
  • Lee J, Aphinyanaphongs Y, Curtin JP, Chern JY, Frey MK, Boyd LR. The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer. Gynecol Oncol. 2016 Sep;142(3):508-513. Pubmedid: 27288543.
  • Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?. Cancer. 2016 Mar;122(6):859-867. Pubmedid: 26938270.
  • Chern JY, Curtin JP. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. CURR TREAT OPTION ON. 2016 Jan;17(1):1. Pubmedid: 26714493.
  • Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015 Nov;139(2):211-215. Pubmedid: 26296696.
  • McLoughlin J, Melis M, Siegel E, Dean E, Weber J, Chern J, Elliott M, Kelley S, Karl R. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg. 2008 May;206(5):879-886. Pubmedid: 18471715.
  • Hohenstein KA, Pyle AD, Chern JY, Lock LF, Donovan PJ. Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells. Stem Cells. 2008 Jun;26(6):1436-1443. Pubmedid: 18323409. Pmcid: PMC3882114.
  • Charron M, Chern JY, Wright WW. The cathepsin L first intron stimulates gene expression in rat sertoli cells. Biol Reprod. 2007 May;76(5):813-824. Pubmedid: 17229931.